J&J Q1 Profit Beats Estimates Despite Stelara Sales Drop

Q1 Earnings Overview

Johnson & Johnson announced first-quarter financial results that surpassed Wall Street expectations, driven by strong pharmaceutical sales. The company reported adjusted earnings of $2.70 per share on revenue of $24.1 billion, exceeding consensus estimates of $2.66 per share and $23.6 billion in revenue.

Despite the positive report, the company's shares saw a marginal decline in premarket trading.

Drug Sales Drive Performance

The impressive performance was largely fueled by cancer drug Darzalex and psoriasis treatment Tremfya. Darzalex sales reached $4.0 billion, while Tremfya brought in $1.6 billion, both significantly beating analysts' forecasts.

However, sales for the blockbuster autoimmune drug Stelara fell approximately 60% to $656 million following its loss of patent protection and subsequent biosimilar competition.

Market Reaction and Updated Forecast

In response to the strong quarter, Johnson & Johnson raised its full-year 2026 revenue forecast to a new midpoint of around $100.8 billion. The company also increased its adjusted earnings outlook to a midpoint of $11.55 per share.

This updated guidance aligns with or slightly exceeds current Wall Street estimates, signaling confidence in its product pipeline.

Strategic Outlook

The results demonstrate J&J's ability to navigate patent expirations by leveraging growth from newer key drugs. The company anticipates treatments like Tremfya will continue to capture market share from competitors and older therapies.

FAQ

Q: Why did Johnson & Johnson's earnings beat estimates despite a major drug's sales decline?
A: Robust demand for cancer drug Darzalex and psoriasis treatment Tremfya more than compensated for the steep fall in Stelara sales.

Q: What caused the decline in Stelara sales?
A: Stelara is facing competition from biosimilar drugs after losing its patent protection last year.

Source: Investing.com